Eph receptor A2 (EPHA2) Human shRNA Plasmid Kit (Locus ID 1969)
CAT#: TR320327
EPHA2 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector, 5µg of each construct provided
Need custom shRNA service?
Get a free quote
CNY 4,790.00
货期*
现货
规格
Cited in 4 publications. |
Product images
经常一起买 (2)
Specifications
Product Data | |
Product Name | Eph receptor A2 (EPHA2) Human shRNA Plasmid Kit (Locus ID 1969) |
Locus ID | 1969 |
UniProt ID | P29317 |
Synonyms | ARCC2; CTPA; CTPP1; CTRCT6; ECK |
Vector | pRS |
Format | Retroviral plasmids |
Kit Components | EPHA2 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 1969). 5µg purified plasmid DNA per construct29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free. |
RefSeq | NM_004431, NM_001329090, NM_004431.1, NM_004431.2, NM_004431.3, NM_004431.4, BC037166, BC037166.2, BC008655, NM_004431.5 |
Summary | This gene belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. EPH and EPH-related receptors have been implicated in mediating developmental events, particularly in the nervous system. Receptors in the EPH subfamily typically have a single kinase domain and an extracellular region containing a Cys-rich domain and 2 fibronectin type III repeats. The ephrin receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. This gene encodes a protein that binds ephrin-A ligands. Mutations in this gene are the cause of certain genetically-related cataract disorders.[provided by RefSeq, May 2010] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (4)
The use of this RNAi has been cited in the following citations: |
---|
Progranulin/EphA2 axis: A novel oncogenic mechanism in bladder cancer
,Buraschi, S;Neill, T;Xu, SQ;Palladino, C;Belfiore, A;Iozzo, RV;Morrione, A;,
Matrix Biol.
,PubMed ID 32417448
[EPHA2]
|
EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma
,Garcia-Monclús, S;López-Alemany, R;Almacellas-Rabaiget, O;Herrero-Martín, D;Huertas-Martinez, J;Lagares-Tena, L;Alba-Pavón, P;Hontecillas-Prieto, L;Mora, J;de Álava, E;Rello-Varona, S;Giangrande, PH;Tirado, OM;,
Int. J. Cancer
,PubMed ID 29582409
[EPHA2]
|
A Modified Adenovirus Vector-Mediated Antibody Screening Method Identifies EphA2 as a Cancer Target
,Tanaka, T;Yamada, H;Kuroki, M;Kodama, S;Tamura, K;Takamatsu, Y;,
Transl Oncol
,PubMed ID 28505517
[EPHA2]
|
A Genome-Wide Screen Reveals Functional Gene Clusters in the Cancer Genome and Identifies EphA2 as a Mitogen in Glioblastoma
,Fenghua Liu, Peter J. Park, Weil Lai, Elizabeth Maher, Arnab Chakravarti, Laura Durso, Xiuli Jiang, Yi Yu, Amanda Brosius, Meredith Thomas, Lynda Chin, Cameron Brennan,Ronald A. DePinho, Isaac Kohane, Rona S. Carroll, Peter M. Black, and Mark D. Johnson,
Cancer Res., Nov 2006; 66: 10815-10823.
[EPHA2]
|
Documents
Product Manuals |
FAQs |
SDS |
Customer
Reviews
Loading...